Osimertinib (OSI) is a registered, selective, and irreversible third-generation EGFR inhibitor specifically prescribed for the management of NSCLC patients possessing the EGFR T790M and L858R mutations5. This evidence concerns the gene EGFR and non-small cell lung carcinoma.